Epiretinal Membrane
Conditions
Keywords
Epiretinal membrane, triamcinolone acetonide
Brief summary
This study compares the anatomical and visual outcomes of patients with idiopathic epiretinal membrane(ERM) treated by vitrectomy and membrane peeling with or without subtenon triamcinolone acetonide injection
Interventions
PROCEDUREVitrectomy only group
The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
PROCEDURECombined therapy group
The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
Sponsors
Yeungnam University College of Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1.The participant must have idiopathic epiretinal membrane 2.The participant must be willing and able to comply with the protocol.
Exclusion criteria
* 1\. The participant has idiopathic epiretinal membrane with other ocular vascular diseases such as Diabetes retinopathy, BRVO, etc. 2\. The participant has any additional ocular diseases that have irreversibly compromised or could likely compromise the visual acuity of the study eye including amblyopia, anterior ischemic optic neuropathy, clinically significant diabetic macular edema, severe non proliferative diabetic retinopathy, or proliferative diabetic retinopathy. 3\. The participant has had intraocular surgery (including lens replacement surgery). 4\. The participant has a history of (within the last six months), or current ocular or periocular infection (including any history of ocular herpes zoster or simplex).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes of best corrected visual acuity and central retinal thickness | 6 months | Changes of best corrected visual acuity and central retinal thickness on optical coherence tomography (OCT) at baseline and 1, 3, 6 months after injection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in status of ISOS line | 6 months | Changes in status of ISOS line on optical coherence tomography (OCT) at baseline and 1, 3, 6 months after injection |
Countries
South Korea
Outcome results
None listed